Debilitating reaction following the initial dose of tramadol

被引:14
作者
Gleason, PP [1 ]
Frye, RF [1 ]
OToole, T [1 ]
机构
[1] UNIV PITTSBURGH,SCH MED,DIV GEN INTERNAL MED,PITTSBURGH,PA 15261
关键词
tramadol;
D O I
10.1177/106002809703101006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To describe a debilitating reaction following a single oral dose of tramadol, CASE SUMMARY: A 32-year-old white man with no prior medical problems, allergies, or previous medication reactions experienced ataxia, dilation of the pupils, numbness in his arms and legs, tremulousness, and dysphoria lasting approximately 4 hours following an initial tramadol dose (100 mg), The patient recovered with no sequelae. DISCUSSION: Central nervous system (CNS) stimulation during therapy with tramadol was reported in 7% of patients in clinical trials. These reactions are usually mild and transient. This report describes a debilitating CNS-mediated reaction to an initial dose of tramadol in an otherwise healthy adult, The patient was phenotyped for CYP2D6 activity, the major metabolic pathway for tramadol elimination, and was determined to be an extensive metabolizer with very high CYP2D6 activity. CONCLUSIONS: The exact mechanism of the adverse response is not known; however, based on phenotyping results, we suspect that it may be related to high concentrations of the active O-desmethyl metabolite of tramadol.
引用
收藏
页码:1150 / 1152
页数:3
相关论文
共 17 条
[1]   PREVALENCE OF CYP2D6 GENE DUPLICATION AND ITS REPERCUSSION ON THE OXIDATIVE PHENOTYPE IN A WHITE-POPULATION [J].
AGUNDEZ, JAG ;
LEDESMA, MC ;
LADERO, JM ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :265-269
[2]  
BARKIN RL, 1995, FORMULARY, V30, P321
[3]   PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN [J].
BERTILSSON, L ;
LOU, YQ ;
DU, YL ;
LIU, Y ;
KUANG, TY ;
LIAO, XM ;
WANG, KY ;
REVIRIEGO, J ;
ISELIUS, L ;
SJOQVIST, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) :388-397
[4]   THE GENETIC-POLYMORPHISM OF DEBRISOQUINE SPARTEINE METABOLISM - CLINICAL ASPECTS [J].
EICHELBAUM, M ;
GROSS, AS .
PHARMACOLOGY & THERAPEUTICS, 1990, 46 (03) :377-394
[5]   A FAMILY AND POPULATION STUDY OF THE GENETIC-POLYMORPHISM OF DEBRISOQUINE OXIDATION IN A WHITE BRITISH-POPULATION [J].
EVANS, DAP ;
MAHGOUB, A ;
SLOAN, TP ;
IDLE, JR ;
SMITH, RL .
JOURNAL OF MEDICAL GENETICS, 1980, 17 (02) :102-105
[6]   Improved high-performance liquid chromatographic determination of debrisoquine and 4-hydroxydebrisoquine in human urine following direct injection [J].
Frye, RF ;
Branch, RA .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1996, 677 (01) :178-182
[7]  
GIBSON TP, 1996, AM J MED S1A, V101, pS47
[8]  
KAISARY A, 1987, CANCER RES, V47, P5488
[9]  
LIAO S, 1992, PHARMACOL RES S, V9, P308
[10]  
*MCNEIL PHARM, 1995, PACK INS ULTR TRAM